Brodalumab

Identification

Name
Brodalumab
Accession Number
DB11776
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
AMG 827 / AMG-827 / KHK-4827 / KHK4827
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SiliqInjection210 mg/1SubcutaneousValeant Pharmaceuticals North America2017-02-15Not applicableUs
SiliqSolution210 mgSubcutaneousValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Categories
UNII
6ZA31Y954Z
CAS number
1174395-19-7

Pharmacology

Indication

Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Associated Conditions
Pharmacodynamics

Increase in the level of IL-17 due to blocking of its receptors.

Mechanism of action

Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Absorption
Not Available
Volume of distribution

4.62 L.

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance

0.223 L/day.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Brodalumab is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Brodalumab is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Brodalumab is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Brodalumab.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Brodalumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Brodalumab is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Brodalumab.Approved
FingolimodBrodalumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Brodalumab is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Brodalumab is combined with GI-5005.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Brodalumab is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Brodalumab is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Brodalumab is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when Brodalumab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Brodalumab is combined with INGN 225.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Brodalumab is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
LeflunomideThe risk or severity of adverse effects can be increased when Brodalumab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Brodalumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brodalumab.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Brodalumab is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brodalumab.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Brodalumab is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Brodalumab.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Brodalumab is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Brodalumab is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Brodalumab is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Brodalumab is combined with Salmonella typhi ty21a live antigen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brodalumab.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Brodalumab is combined with SRP 299.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Brodalumab.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Brodalumab is combined with Tecemotide.Investigational
TG4010The risk or severity of adverse effects can be increased when Brodalumab is combined with TG4010.Investigational
TofacitinibBrodalumab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Brodalumab.Approved, Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Brodalumab is combined with Typhoid Vaccine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Brodalumab is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Brodalumab is combined with Yellow Fever Vaccine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. article [Link]
  2. article [Link]
External Links
KEGG Drug
D10061
PubChem Substance
347911240
Wikipedia
Brodalumab
ATC Codes
L04AC12 — Brodalumab
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailablePsoriasis1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPsoriasis2
1WithdrawnBasic ScienceAsthma Bronchial1
1, 2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentModerate to Severe Plaque Psoriasis1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentCrohn's Disease (CD)2
2TerminatedTreatmentPsoriasis1
2TerminatedTreatmentPsoriatic Arthritis1
2TerminatedTreatmentRheumatoid Arthritis1
2WithdrawnTreatmentSpondyloarthritis, Axial1
3Active Not RecruitingTreatmentModerate to Severe Plaque Psoriasis1
3Active Not RecruitingTreatmentSpondyloarthritis, Axial1
3CompletedTreatmentPsoriasis2
3CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis) / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular Psoriasis / Pustular; Psoriasis, Palmaris Et Plantaris1
3CompletedTreatmentPsoriatic Arthritis1
3TerminatedTreatmentModerate to Severe Plaque Psoriasis3
3TerminatedTreatmentPsoriasis1
3TerminatedTreatmentPsoriatic Arthritis1
4Not Yet RecruitingTreatmentPsoriasis1
4RecruitingTreatmentPsoriasis1
4RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableNot Yet RecruitingNot AvailablePsoriasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous210 mg/1
SolutionSubcutaneous210 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on July 16, 2018 21:28